Caas Capital Management LP Arcellx, Inc. Transaction History

Caas Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$31.51 - $37.4 $3.94 Million - $4.67 Million	124,959 New	124,959 $4.48 Million
Q1 2023 May 15, 2023	SELL	$26.92 - $33.94 $134,600 - $169,700	-5,000 Reduced 3.85%	124,959 $3.85 Million
Q4 2022 Feb 14, 2023	BUY	$17.18 - $33.0 $2.23 Million - $4.29 Million	129,959 New	129,959 $4.03 Million
Q2 2022 Aug 15, 2022	SELL	$7.21 - $24.43 $1.97 Million - $6.68 Million	-273,412 Reduced 67.59%	131,083 $2.37 Million
Q1 2022 May 13, 2022	BUY	$12.97 - $19.14 $5.25 Million - $7.74 Million	404,495 New	404,495 $5.67 Million

204

44.2M

2.23M

907K

Ticker ACLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,819,200
Market Cap $3.31B
Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Caas Capital Management LP with notifications on news.